Popular terms

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      

This page is updated frequently with new Kinetics-related patent applications.




Date/App# patent app List of recent Kinetics-related patents
02/04/16
20160033523 
 Pharmacokinetic animal model patent thumbnailnew patent Pharmacokinetic animal model
The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for hsa binding to the fcrn receptor in said animal. In the non-primate animal species, the binding affinity of wild type hsa to the native fcrn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native fcrn.
University Of Oslo


02/04/16
20160031983 
 Methods for treating crohn's disease using an anti-il23 antibody patent thumbnailnew patent Methods for treating crohn's disease using an anti-il23 antibody
The invention relates to products and methods for treating crohn's disease. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Amgen Inc.


02/04/16
20160030592 
 Polyoxazoline antibody drug conjugates patent thumbnailnew patent Polyoxazoline antibody drug conjugates
In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer adcs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (dar) of the antibody significantly beyond the currently available technology.
Serina Therapeutics, Inc.


01/28/16
20160024573 
 Photocleavable deoxynucleotides with high-resolution control of deprotection kinetics patent thumbnailPhotocleavable deoxynucleotides with high-resolution control of deprotection kinetics
Provided herein are new classes of photocleavable deoxynucleotides that allow for more precise control over deprotection kinetics compared to previously described compounds. The compounds further feature more favorable solubility properties.
Ibis Biosciences, Inc.


01/28/16
20160022817 
 Photoswitchable hdac inhibitors patent thumbnailPhotoswitchable hdac inhibitors
This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of hdac having photoswitchable modulators of protein function with short thermal relaxation kinetics.
The General Hospital Corporation


01/28/16
20160022169 
 Determination of physiological parameters of tissue from dynamic contrast-enhanced mr data patent thumbnailDetermination of physiological parameters of tissue from dynamic contrast-enhanced mr data
A method of determining microvascular architecture is disclosed. Dynamic contrast-enhanced magnetic resonance data acquired from a contrast agent administered to at least a part of a subject to be examined.
Koninklijke Philips N.v.


01/21/16
20160016821 
 Novel cross-linked (bisphenol-s, formaldehyde, 1,6-hexadiamine) terpolymer for the adsorption of pb2+  ions from aqueous solutions patent thumbnailNovel cross-linked (bisphenol-s, formaldehyde, 1,6-hexadiamine) terpolymer for the adsorption of pb2+ ions from aqueous solutions
A cross-linked terpolymer (bsdf) obtained by polycondensation of bisphenol-s, formaldehyde and 1,6-diaminohexane. The terpolymer is highly efficient in eliminating lead ions from aqueous solutions.
King Fahd University Of Petroleum And Minerals


01/21/16
20160015698 
 Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters patent thumbnailPharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose auc(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose auc(2-10) of an immediate release composition of donepezil administered in the night, wherein both the compositions have equivalent dose of donepezil.. .
Lupin Limited


01/14/16
20160011169 
 Nanopore sequencing methods patent thumbnailNanopore sequencing methods
Methods are provided for sequencing of nucleic acid templates using nanopores. The rate of transport of the template nucleic acids through the nanopore is controlled using a polymerase enzyme having two slow kinetic steps.
Pacific Biosciences Of California, Inc.


01/14/16
20160010148 
 Identifying modified bases using hemi-natural nucleic acids patent thumbnailIdentifying modified bases using hemi-natural nucleic acids
Methods, compositions, and systems are provided for characterization of modified nucleic acids. Methods are provided for sequencing hemi-natural nucleic acids such as hemi-genomic dna, having two complementary strands, one a natural sequence and the other a synthetic sequence.
Pacific Bioscience Of California, Inc.


01/14/16
20160009818 

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics


Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
Bayer Healthcare Llc


01/14/16
20160008341 

Crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations


The present invention relates to the crystalline mono mesylate monohydrate salt of n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof..
Aicuris Gmbh & Co. Kg


01/14/16
20160008335 

Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters


A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° c., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.. .
Lupin Limited


01/07/16
20160000923 

Drug delivery system to increase bioavailability


Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.. .
Patheon Inc.


01/07/16
20160000806 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


01/07/16
20160000704 

Formulations of human tissue kallikrein-1 for parenteral delivery and related methods


Provided are high concentration compositions of tissue kallikrein-1 (klk1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human klk1 (rhklk1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof..
Diamedica Inc.


12/31/15
20150377894 

Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin


The present invention includes a stabilized curcumin composition. The composition includes a curcumin composition and a phosphate composition, wherein the phosphate composition is non-buffering and is provided in an amount sufficient to stabilize and/or prevent the degradation of curcumin and/or a curcuminoid in a biological sample..
Signpath Pharma Inc.


12/31/15
20150376803 

Gas diffusion electrodes and methods for fabricating and testing same


Highly effective, standalone gas-diffusion electrodes (gdes) and the methods for their manufacture and test are disclosed, nanocataiysis are directly bonded on a gas diffusion layer, so that the integrity of the catalyst layer holds without polymer electrolyte membrane, facilitating minimization of electronic, prottmtc, and diffusion resistances in the catalyst layer. The devised embodiments provide examples showing a facile hanging-strip method for testing the standalone gdes in a solution electrochemical cell, which removes the ma-cm−2-scale mass transport limited currents on rotating disk electrodes to allow studies of reaction kinetics on single electrode over sufficiently wide current ranges (up to a cm−2) without mass transport limitation.
Brookhaven Science Associates, Llc


12/31/15
20150376509 

Enhanced catalytic reactions in a coking process to improve process operation and economics


Heavy gas oil components, coking process recycle, and heavier hydrocarbons in the delayed coking process are cracked in the coking vessel by injecting a catalytic additive into the vapors above the gas/liquid-solid interface in the coke drum during the coking cycle. The additive may comprise cracking catalyst(s) and quenching agent(s), alone or in combination with seeding agent(s), excess reactant(s), carrier fluid(s), or any combination thereof to modify reaction kinetics to preferentially crack these components.

12/31/15
20150374722 

Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration


An oral dosage form comprising a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed. A method of elevating and sustaining the blood level concentration of 25-hydroxy-vitamin d3 in a human in need thereof comprising orally administering or parenterally administering by injection or infusion, at least once every 7 days, a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days, wherein the single doses orally administered at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.
Wisconsin Alumni Research Foundation


12/24/15
20150370962 

Pharmaceutical platform technology for the development of natural products


The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components..
Sinoveda Canada Inc.


12/24/15
20150368393 

Process for the extraction of polyhydroxyalkanoates from biomass


An industrial scale batch or semi-continuous batch pha extraction process wherein the process operating conditions and control may be quantitatively tuned to batch-to-batch variations based on a practical bench scale assessment but more preferably by means of a calibrated chemometric assessment of the biomass quality. Tuning involves the selection of biomass loading conditions that are commensurate with process solvent and pha type.
Veolia Water Solutions & Technologies Support


12/24/15
20150366849 

Crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations


The present invention relates to the crystalline mono mesylate monohydrate salt of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof..
Aicuris Gmbh & Co. Kg


12/17/15
20150361091 

Oxazolidone compound, preparing method and application thereof


The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage.
Zhe Jiang Jutai Pharmaceutical Co., Ltd


12/10/15
20150353911 

Chimeric clotting factors


The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation.
Biogen Idec Ma Inc.


12/10/15
20150353693 

Rapid fabrication of hierarchically structured supramolecular nanocomposite thin films in one minute


Functional nanocomposites containing nanoparticles of different chemical compositions may exhibit new properties to meet demands for advanced technology. It is imperative to simultaneously achieve hierarchical structural control and to develop rapid, scalable fabrication to minimize degradation of nanoparticle properties and for compatibility with nanomanufacturing.
The Regents Of The University Of California


12/10/15
20150352128 

Controlled release and taste masking oral pharmaceutical composition


Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. A structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices.
Cosmo Technologies Limited


12/03/15
20150346104 

Sensing device, and sensing system and sensing method using the same


A sensing device applied to an analyte molecule of a liquid sample and a buffer flow has at least one first inlet, at least one second inlet, a micro-flow channel, and at least one immobilization element. The first inlet is for inputting the liquid sample.
Centre National De La Recherche Scientifique


12/03/15
20150343074 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


12/03/15
20150343073 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


12/03/15
20150343072 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


11/26/15
20150335954 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/26/15
20150335953 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/26/15
20150335952 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/19/15
20150332004 

Method and system to identify frailty using body movement


Systems and methods are disclosed which provide a way to diagnose frailty using an upper extremity (and/or other body portions) frailty assessment. Within this method, several parameters can be calculated based on the kinematics (e.g., pure motion without including forces) and kinetics (e.g., analysis of forces and moments) of, for example, joint flexion/extension.
The Arizona Board Of Regents On Behalf Of The University Of Arizona


11/19/15
20150328369 

Method of treating peripheral artery diseases in lower limbs


A method of treating peripheral artery diseases in lower limbs by providing a medical device having an expandable member having a drug coating layer which has a crystalline morphological form including a plurality of crystal particles of a water-insoluble drug regularly arranged and uniformly sized on the surface of the medical device, inserting the medical device in peripheral blood vessels, expanding the expandable member, pressing the drug coating layer to a blood vessel wall such that at least part of the plurality of crystals are transferred to the blood vessel wall, and deflating the expandable member such that a pharmacokinetics profile is presented in which a drug concentration in the blood vessels is kept for the inhibition of smooth muscle cell proliferation in a high drug-concentration period of time, and for the non-inhibition of endothelial cell growth in a later low drug-concentration period of time.. .
Terumo Kabushiki Kaisha


11/05/15
20150316533 

Methods and systems for point-of-care coagulation assays by optical detection


This invention relates to an optical system and method for performing turbidity assay, e.g. Coagulation of blood or plasma, comprising a standard optical reference, a sample handling structure, a light source and an optical detection unit.

11/05/15
20150315278 

Anti-glypican-3 antibody having improved kinetics in plasma


A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient..
Chugai Seiyaku Kabushiki Kaisha


11/05/15
20150314010 

Potentiation of anticancer agents


The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer..
Angiochem Inc.


10/22/15
20150302169 

Method and system to extend the conditions of application of an inversion of the hodgkin-huxley gating model


A method to quantify kinetics of voltage gated membrane channels by inversion of a hodgkin huxley formalism includes the steps of: providing an electrophysiology apparatus configured to provide a constant voltage difference across a cell membrane of a cell and to measure a current through the cell membrane and a computer configured to run at least one or more protocols; bounding r based on data generated by a t-step protocol or a g-step protocol; estimating a steady state based on data generated by a c-step protocol or a h step protocol; extracting a time constant based on the data generated by the t-step protocol or the g-step protocol as bounded by r; and assessing a range of time constants that can reproduce the data generated by the c-step protocol or the h step protocol and by the t-step protocol or the g-step protocol within and experimental error. C-step and a g-step voltage clamp stimulation protocols to generate a set of experimental data to quantify a channel availability of a cell are also described..

10/22/15
20150299313 

Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain


Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the ph of early-stage endosome compared to the antigen-binding activity in the ph of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind.
Chugai Seiyaku Kabushiki Kaisha


10/22/15
20150299305 

Anti-c5 antibodies having improved pharmacokinetics


The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..
Alexion Pharmaceuticals, Inc.


10/15/15
20150293110 

Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent


The disclosure is directed to compositions, kits, and methods for performing colorimetric analysis. A composition for a colorimetric assay can be prepared that includes an aromatic amine chromogenic substrate and a zwitterionic solubilization reagent that is n,n,n-trimethylglycine (betaine).

10/15/15
20150293077 

Methods for determining the effect of an agent on tissue stem cells


Herein, we describe a direct in vitro method that identifies agents that are toxic against natural human tissue stem cells. We provide a novel schedule for culturing any cell population containing homologous tissue stem cells that allows the number and cell kinetics of tissue stem cells, transient cells, and terminally differentiated cells within the population to be monitored.

10/15/15
20150291596 

Antiviral azasugar-containing nucleosides


Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral rna polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration.

10/15/15
20150290328 

Formulations of active agents for sustained release


The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs..

10/08/15
20150284518 

Enhancing the physical properties of semi-crystalline polymers via solid state shear pulverization


Solid-state shear pulverization of semi-crystalline polymers and copolymers thereof and related methods for enhanced crystallization kinetics and physical/mechanical properties.. .

10/08/15
20150284465 

Method of modifying isoelectric point of antibody via amino acid substitution in cdr


The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (cdr). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point.

10/08/15
20150284352 

Methods for inhibiting drug degradation


Methods of inhibiting cytochrome p450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome p450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome p450 enzymes..

10/08/15
20150283294 

Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents


Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid.

10/01/15
20150274809 

Antibody constant region variant


By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity.
Chugai Seiyaku Kabushiki Kaisha


10/01/15
20150272900 

Layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics


A layer-by-layer (lbl) system, which alternately ionically complexes anionic aunps to two unique cationic polymers (disuifide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.. .
The Johns Hopkins University


09/24/15
20150268227 

Quantitative measurement of human blastocyst and morula morphology developmental kinetics


Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans..
Auxogyn, Inc.


09/24/15
20150265538 

Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets


The present invention relates inter alia to the use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolution kinetics (dissolution) and/or the water loading of tablets.. .
Boehringer Ingelheim International Gmbh


09/17/15
20150263216 

Device and restoring silicon-based solar cells using an ultrasound transducer


The restoration device of least one silicon-based photovoltaic solar cell includes a support of the cell, a heat source configured to heat the photovoltaic solar cell, and unit for generating charge carriers in the cell. To better accelerate the restoration kinetics of the solar cell, the device includes an ultrasonic transducer designed to generate ultrasonic waves propagating in the photovoltaic solar cell..
Commissariat A L'energie Atomique Et Aux Energies Alternatives


09/17/15
20150259397 

Long acting trial receptor agonists for treatment of autoimmune diseases


Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory t cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a trail-conjugate. Preferably, the trail-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the trail-conjugate.
Theraly Pharmaceuticals Inc.


09/17/15
20150258137 

Plasma and brain pharmacokinetics of previously unexplored lithium salts


Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities.
University Of South Florida


09/10/15
20150254421 

Methods of diagnosing amyloid pathologies using analysis of amyloid-beta enrichment kinetics


A method of diagnosing an amyloid pathology in the central nervous system of a patient using measurements of enrichment kinetics of at least one amyloid-β isoform is provided. In addition, a model to predict enrichment kinetics of at least one amyloid-β isoform, methods of calibrating the model, and methods of using the model to diagnosing an amyloid pathology in the central nervous system of a patient are provided..
Washington University


09/10/15
20150253275 

Electric-field enhanced performance in catalysis and solid-state devices involving gases


Electrode configurations for electric-field enhanced performance in catalysis and solid-state devices involving gases are provided. According to an embodiment, electric-field electrodes can be incorporated in devices such as gas sensors and fuel cells to shape an electric field provided with respect to sensing electrodes for the gas sensors and surfaces of the fuel cells.
University Of Florida Research Foundation, Incorporated


09/10/15
20150251353 

Method for printing three-dimensional items wtih semi-crystalline build materials


A method for printing a three-dimensional part with an additive manufacturing system includes providing a consumable feedstock material comprising a semi-crystalline polymer containing one or more secondary materials, wherein the consumable feedstock material has a process window in which crystalline kinetics are either accelerated or retarded. The consumable feedstock material is melted in the additive manufacturing system.
Stratasys, Inc.


09/03/15
20150247136 

Polymerase compositions and methods


Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions.
Life Technologies Corporation


09/03/15
20150246133 

Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides


Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetragalnac ligands of formula (i), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.. .
Sima Therapeutics, Inc.


08/27/15
20150240214 

Induction of pluripotent cells


The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (ipscs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of ipsc generation from human fibroblasts, within seven days of treatment.
The Scripps Research Institute


08/27/15
20150239952 

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same


The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention.
Stc.unm


08/20/15
20150233938 

Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry


Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites in living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices..
The Regents Of The University Of California


08/20/15
20150233809 

Device and determining the dissolution kinetics of colloidal nanoparticles


A device is described for determining the dissolution kinetics of colloidal nanoparticles in respective derivation ions in a solution, which comprises a dissolution compartment containing the solution, and feedable with the colloidal nanoparticles; an analysis compartment separate from the dissolution compartment; a fixed filtering membrane which separates the dissolution compartment from the analysis compartment, is selectively permeable to the derivation ion and is adapted to filter the solution; compressing means to induce passage of the solution from the dissolution compartment to the analysis compartment through the filtering membrane; a determination device for determining the quantity of the derivation ion; the device furthermore comprises mixing means associated to the dissolution compartment and distinct from the compressing means and the filtering membrane has pores of size smaller than 10 nm. Relative determination methods for determining the dissolution kinetics and the toxicity of colloidal nanoparticles are also described..
Fondazione Istituto Italiano Di Tecnologia


08/20/15
20150232576 

Endothelial nitric oxide synthase


Endothelial nitric oxide synthase (enos) activity was modulated by contact with an effective amount of a mitogen-activated protein (map) kinase, resulting in phosphorylation of s602, t46, and/or s58. kinetics and stoichiometry are disclosed.
Kennesaw State University Research And Services Foundation, Inc.


08/13/15
20150226621 

System and head acceleration measurement in helmeted activities


The present invention generally relates to a system and method for the precise measurement of acceleration, movement, and other forces imparted on a body or object. Specifically, the invention relates to a system and method for measuring head accelerations in helmeted activities including, but not limited to, football, ice hockey, and lacrosse.
Evigia Systems, Inc.


08/13/15
20150225656 

System and introducing an additive with a unique catalyst to a coking process


Gas oil components, coking process recycle, and heavier hydrocarbons are cracked or coked in the coking vessel by injecting an additive into the vapors of traditional coking processes in the coking vessel. The additive contains catalyst(s), seeding agent(s), excess reactant(s), quenching agent(s), carrier(s), or any combination thereof to modify reaction kinetics to preferentially crack or coke these components.

08/13/15
20150225263 

Electrokinetic process and consolidation of oil sands tailings


A method is provided of treating liquid tailings using electro-kinetics by creating a variable voltage between two electrodes in the tailings. Flocculation and water release from the tailings is induced by establishing an electrical field between the two electrodes.
Electro-kinetic Solutions, Inc.


08/06/15
20150219635 

Method for identifying compounds of therapeutic interest


The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) providing a test compound which has a low molecular weight, (c) evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) select a compound from step c) based on the ability to bind to the protein or fragment thereof..
Ucb Pharma S.a.


08/06/15
20150218653 

Method of determining the presence or absence of a target nucleic acid in a cell sample


A method of determining the presence or absence of a target nucleic acid in a cell sample, said method comprising: a) contacting a surface comprising anion exchange moieties with the sample under conditions suitable to induce binding between the cells and said surface; b) separating the surface with the bound cells from the remaining sample to collect the cells; c) releasing nucleic acids from the cells and d) generating a hybrid between the target nucleic acid and a probe specific for the target nucleic acid e) detecting the presence or absence of the hybrid. The present invention is provides a rapid and automatable method, wherein cells, such as epithelial cells originating from cervical swab samples, are collected from the surrounding liquid medium, such as a liquid based cytology medium, by binding them to an anion exchange surface.
Qiagen Gmbh


08/06/15
20150218615 

Methods for detecting organisms and enzymatic reactions using raman spectroscopy and aromatic compounds comprising phosphate


The present disclosure provides systems for the rapid and sensitive detection of organisms and molecules in samples. Reactants that produce raman-active products are used in combination with raman light scattering.
Sword Diagnostics, Inc.


08/06/15
20150217126 

Method and electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans


Apparatus and methods for delivering electromagnetic signals configured specifically to accelerate the asymmetrical kinetics of the binding of intracellular ions to their respective intracellular buffers, to enhance the biochemical signaling pathways plant animal and human molecules, cells, tissues, organs, portions of entire organisms and entire organisms employ for growth, repair and maintenance. Described herein are devices and methods that utilize repetitive bursts of waveforms configured to maximize the bound concentration of intracellular ions at their associated molecular buffers to enhance the biochemical signaling pathways living systems employ for growth, repair and maintenance.

07/30/15
20150209442 

Method to improve pharmacokinetics of drugs


A compound comprises a pharmacologically active agent coupled to a plasma protein binding agent. The pharmacologically active agent, in some embodiments, may be an olam inhibitor.
The Board Of Regents Of The University Of Texas System


07/30/15
20150208982 

Methods for making controlled delivery devices having zero order kinetics


A method of making an injectable or implantable active agent delivery device capable of delivering a diagnostic, therapeutic, and/or prophylactic agent to a desired targeted site having orifice(s) on the surface is disclosed herein providing unidirectional release of the agent at a controlled desirable rate. The agent may include, but is not limited to, drugs, proteins, peptides, biomarkers, bioanalytes, and/or genetic material.
Board Of Regents, The University Of Texas System


07/23/15
20150203843 

Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides


Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetragalnac ligands of formula (i), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.. .
Sirna Therapeutics, Inc.


07/23/15
20150203562 

Compounds and methods for modulating pharmacokinetics


Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (hb). Compounds may be administered to tissues including skin.
The Brigham And Women's Hospital, Inc.


07/16/15
20150197531 

Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug


And pharmaceutically acceptable salts thereof, wherein a, w, x, r1, r2, r3, r4 and r5 are as defined herein. The present invention also relates to compositions comprising at least one sulfonamide derivative, and methods of using the sulfonamide derivatives for improving the pharmacokinetics of a drug..

07/16/15
20150196589 

Formulations for alteration of biophysical properties of mucosal lining


Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation.
Pulmatrix, Inc.


07/16/15
20150196247 

Systems for monitoring infant oral motor kinetics during nutritive and non-nutritive feeding


The present invention relates to a system device and method for monitoring infant oral motor kinetics (omk), which can be used to assess the functional significance of the different sucking components, i.e., the plasticity of infant sucking skills in relation to their oral feeding performance, at a particular time, during the developmental period and/or during preventive or therapeutic intervention programs. It is a unique system and apparatus that provides a means to study the nonnutritive and/or nutritive sucking skills, i.e., the suction and/or expression components of sucking, of infants in the natural setting, i.e., during a normal feeding session.

07/09/15
20150190279 

Therapeutics dispensing device and methods of making same


A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics.
Baylor College Of Medicine


07/02/15
20150187638 

Process for transferring a layer


This transfer process comprises the following steps: (a) providing a donor substrate and a support substrate; (b) forming an embrittlement region in the donor substrate; (c) forming what is called a bonding layer between the first part of the donor substrate and the support substrate; and assembling the donor substrate to the support substrate, and is noteworthy in that it comprises the following step: (e) exposing, in succession, portions of the embrittlement region to electromagnetic irradiations for an exposure time at a given power density, the exposure time being chosen depending on the thickness of the bonding layer so that the support substrate is thermally decoupled from the first part of the donor substrate, the exposure time being chosen depending on the power density in order to activate kinetics that weaken the embrittlement region.. .
Soitec


07/02/15
20150185235 

Blood factor monitoring assay and uses thereof


The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate.
Biogen Idec Ma Inc.


07/02/15
20150185216 

Systemic discovery, maturation and extension of peptide binders to proteins


The invention comprises systems, methods and arrays for identification and optimization of novel peptide binders to protein targets. Embodiments include steps of peptide binder discovery, core peptide maturation, n-terminal and c-terminal extension and kinetics analysis of the final peptide binder..
Roche Nimblegen Inc.




Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.


4.7507

4634

3 - 0 - 103